Form 4: Madrigal Pharmaceuticals Executive Carole Huntsman Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Carole Huntsman, Chief Commercial Officer of Madrigal Pharmaceuticals, sold shares of common stock on March 3, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Carole Huntsman, Chief Commercial Officer of Madrigal Pharmaceuticals, sold shares of the company's common stock on March 3, 2025.
- The sales were executed under a Rule 10b5-1 trading plan adopted on November 5, 2024.
- A total of 2,471 shares were sold at varying prices, ranging from $313.08 to $335 per share.
- Following the transactions, Huntsman directly owns 8,604 shares of Madrigal Pharmaceuticals' common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating insider stock sales. It is neutral in sentiment as it simply reports transactions.
Industry Context
Executive stock sales are a common occurrence in publicly traded companies and are often related to personal financial planning. The use of a 10b5-1 trading plan allows insiders to sell shares without being accused of trading on non-public information.
Stakeholder Impact
- The stock sale could have a minor negative impact on shareholder sentiment, although it is unlikely to be significant given the use of a 10b5-1 plan.
Key Dates
| Date | Description |
|---|---|
| 11/05/2024 | Date of adoption of Rule 10b5-1 trading plan |
| 03/03/2025 | Date of stock sale transactions |
| 03/05/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.